Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.47 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | GPR3 | P46089 | 1/20 | 0.37 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 4/20 | 0.33 |
| ▸ | GLA | P06280 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1451027 | 0.74 | BRPF1 (0.50) | CA12BRD4BRPF1CA9KAT2B | |
| SCHEMBL193935 | 0.70 | GPR3 (0.37) | CA12BRD4BRPF1CA9KAT2B | |
| SCHEMBL3209745 | 0.67 | NOTUM (0.47) | BRPF1BRD9KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL637143 | 0.65 | CA12 (0.53) | CA12BRD4BRPF1CA9KAT2B | |
| SCHEMBL29580418 | 0.64 | KDM4E (0.51) | CA12BRD4BRPF1CA9KAT2B | |
| SCHEMBL6390410 | 0.64 | KDM4E (0.51) | CA12BRD4BRPF1CA9KAT2B | |
| SCHEMBL700437 | 0.64 | GPR3 (0.41) | CA12BRD4BRPF1CA9KAT2B | |
| SCHEMBL248619 | 0.64 | BRPF1 (1.00) | CA12BRD4BRPF1CA9KAT2B | |
| SCHEMBL29967380 | 0.64 | BRPF1 (1.00) | CA12BRD4BRPF1CA9KAT2B | |
| SCHEMBL31093975 | 0.63 | GABRA5 (0.55) | CA12BRD4BRPF1CA9KAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090593-B2 | Bicyclic compounds as Pim inhibitors | AMGEN INC. (US) | 2015-07-28 | — | — | US | claimed |
| US-20140171455-A1 | Reduction of Microglia-Mediated Neurotoxicity by Kv1.3 Inhibition | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-06-19 | — | — | US | claimed |
| EP-2717871-A2 | REDUCTION OF MICROGLIA-MEDIATED NEUROTOXICITY BY KV1.3 INHIBITION | The Regents of the University of California (US) | 2014-04-16 | — | — | EP | claimed |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2014-01-30 | — | — | US | claimed |
| WO-2012170917-A2 | REDUCTION OF MICROGLIA-MEDIATED NEUROTOXICITY BY KV1.3 INHIBITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-12-13 | — | — | WO | claimed |
| US-5371074-A | Use of saccharin derivatives as proteolytic enzyme inhibitors | STERLING WINTHROP INC. (US) | 1994-12-06 | — | — | US | claimed |
| US-9090593-B2 | Bicyclic compounds as Pim inhibitors | AMGEN INC. (US) | 2015-07-28 | — | — | US | disclosed |
| EP-2796456-A1 | Bicyclic compounds as Pim inhibitors | Amgen Inc. (US) | 2014-10-29 | — | — | EP | disclosed |
| US-20140171455-A1 | Reduction of Microglia-Mediated Neurotoxicity by Kv1.3 Inhibition | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2014-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171455-A1 | Reduction of Microglia-Mediated Neurotoxicity by Kv1.3 Inhibition | KCNMA1, KCNN1, KCNN3 | CA12 1272/4885BRD4 1755/4885BRPF1 1931/4885 |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | PIM1, PIM2, PIM3 | CA12 4181/4885BRD4 138/4885BRPF1 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.